title: Stabilization of tooth movement by administration of reveromycin A to osteoprotegerin-deficient knockout mice.
abstract: BACKGROUND
  In this study, mechanical stress in the form of tooth movement was applied to osteoprotegerin-deficient knockout mice, which served as an animal model for juvenile Paget's disease. To compare and evaluate bone turnover and response of the surrounding bony tissue, we administered reveromycin A. We also investigated the ability of reveromycin A to control osteoclastic activity in juvenile Paget's disease.
  
  
  METHODS
  Eight-week-old male osteoprotegerin-deficient knockout and wild-type mice were injected with reveromycin A (15 mg/kg of body weight) intraperitoneally twice daily. An elastic module was inserted interproximally between the maxillary left first and second molars.
  
  
  RESULTS
  Administration of reveromycin A to osteoprotegerin-deficient knockout mice reduced tooth movement distances, increased bone volumes at the interradicular septum, decreased osteoclast counts, and reduced serum alkaline phosphatase and tartrate resistant acid phosphatase. Reveromycin A administration also caused a temporal shift in peak Runx2 staining in osteoprotegerin-deficient knockout mice so that the overall staining time course was similar to that observed for wild-type mice.
  
  
  CONCLUSIONS
  Reveromycin A administration in osteoprotegerin-deficient knockout mice inhibited bone resorption and normalized bone formation. As a result, normal bone turnover was obtained.
authors.affiliation: Department of Orthodontics, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yabumoto
authors.forename: Ken
authors.initials: K
authors.lastname: Miyazawa
authors.forename: Masako
authors.initials: M
authors.lastname: Tabuchi
authors.forename: Satsuki
authors.initials: S
authors.lastname: Shoji
authors.forename: Miyuki
authors.initials: M
authors.lastname: Tanaka
authors.forename: Manami
authors.initials: M
authors.lastname: Kadota
authors.forename: Mamoru
authors.initials: M
authors.lastname: Yoshizako
authors.forename: Makoto
authors.initials: M
authors.lastname: Kawatani
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Osada
authors.forename: Hatsuhiko
authors.initials: H
authors.lastname: Maeda
authors.forename: Shigemi
authors.initials: S
authors.lastname: Goto
mesh_terms: D016301:Alveolar Bone Loss / Q000517:prevention & control*; D000818:Animals; D050256:Antimitotic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects*; D050659:Core Binding Factor Alpha 1 Subunit; D003799:Dental Stress Analysis; D004195:Disease Models, Animal; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D010001:Osteitis Deformans / Q000188:drug therapy; D053244:Osteoprotegerin / Q000172:deficiency*; D011714:Pyrans / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D055502:Secondary Prevention; D013141:Spiro Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014087:Tooth Movement Techniques
chemical_list: D050256:Antimitotic Agents; D050659:Core Binding Factor Alpha 1 Subunit; D053244:Osteoprotegerin; D011714:Pyrans; D013141:Spiro Compounds; C068098:reveromycin A